RecruitingPhase 2NCT07296484

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Studying OBSOLETE: Cushing syndrome

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sparrow Pharmaceuticals
Intervention: clofutriben(drug)
Enrollment: 1500 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2028

Study locations (30)

Arizona Clinical Trials - Pecos, Chandler, Arizona, United States
Arizona Clinical Trials - Broadway, Tucson, Arizona, United States
Ark Clinical Research - Fountain Valley, Fountain Valley, California, United States
Velocity Clinical Research, Huntington Park, Huntington Park, California, United States
Velocity Clinical Research - Gardena, La Mesa, California, United States
Ark Clinical Research - Long Beach, Long Beach, California, United States
Los Angeles Institute for Metabolic Research, Los Angeles, California, United States
Velocity Clinical Research, Los Angeles, Los Angeles, California, United States
Amicis Research Center- Nordhoff, Northridge, California, United States
Velocity Clinical Research, New Smyrna Beach, Edgewater, Florida, United States
The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States
Admed Research LLC, Miami, Florida, United States
Progressive Medical Research, Port Orange, Florida, United States
IACT Health-Brookstone Centre Pkwy, Columbus, Georgia, United States
Chicago Clinical Research Institute, Chicago, Illinois, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07296484 on ClinicalTrials.gov

Other trials for OBSOLETE: Cushing syndrome

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Cushing syndrome →

← Back to all trials